LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

5.09 3.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.9399999999999995

Max

5.18

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+17.78% upside

Turustatistika

By TradingEconomics

Turukapital

92M

593M

Eelmine avamishind

2.05

Eelmine sulgemishind

5.09

Uudiste sentiment

By Acuity

17%

83%

25 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. dets 2025, 23:54 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22. dets 2025, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Correction to Alphabet to Buy Intersect Article

22. dets 2025, 17:21 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22. dets 2025, 16:46 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion in Cash

22. dets 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22. dets 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22. dets 2025, 22:30 UTC

Tulu

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 21:37 UTC

Omandamised, ülevõtmised, äriostud

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22. dets 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Acquire Prospective Package From Tempest Minerals

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22. dets 2025, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22. dets 2025, 20:52 UTC

Omandamised, ülevõtmised, äriostud

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22. dets 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22. dets 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22. dets 2025, 19:49 UTC

Omandamised, ülevõtmised, äriostud

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22. dets 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22. dets 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22. dets 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22. dets 2025, 18:30 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22. dets 2025, 18:23 UTC

Omandamised, ülevõtmised, äriostud

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22. dets 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22. dets 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

17.78% tõus

12 kuu keskmine prognoos

Keskmine 5.83 USD  17.78%

Kõrge 7.5 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

25 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat